The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

Help your website visitors find a certified physician, counselor
or request a resource kit by adding a banner to your website

This convenient shortcut banner can easily be added to your existing website. It provides a simple way for your visitors to find buprenorphine treatment resources without the need to navigate through our entire site. Choose from the banners below for the one that best fits your website design. We would appreciate it very much if you would email us once the banner is on your site, or to report any problems. Thank you! banners@naabt.org

NOTE: If you would like to add our banners to Social networking sites (i.e. MySpace, Facebook, etc.) please use the code provided on this page instead.

Webmasters: If you hate Flash, we have alternative for you, Javascript (or you could use the versions we provide for MySpace users but we prefer you use the Flash or Javascript versions).

180 x 150


468 x 60


120 x 90


93 x 70


119 x 45


180 x 150


468 x 60


120 x 90


93 x 70


119 x 45


180 x 150


468 x 60


120 x 90


93 x 70


119 x 45


180 x 150


468 x 60


120 x 90


93 x 70


119 x 45


This page was last modified on : 10/29/2013

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release